Table 1 Characteristics and gene targets for oncology medicines approved by FDA

CDxs^a

ALK

3 (7.1)

–

BCR-ABL+

1 (2.4)

–

BCR-ABL−

1 (2.4)

–

BRAF

4 (11.9)

–

BRCA

2 (4.8)

–

EGFR

3 (7.1)

–

EZH2

1 (2.4)

–

FGFR

1 (2.4)

–

FLT3+

2 (4.8)

–

HER2+

8 (19.0)

–

HER2−

3 (7.1)

–

IDH1

1 (2.4)

–

IDH2

1 (2.4)

–

MET

1 (2.4)

–

NTRK

2 (4.8)

–

PDGFRA

1 (2.4)

–

PD-L1

3 (7.1)

–

PIK3CA

1 (2.4)

–

RAS

1 (2.4)

–

RET

2 (4.8)

–

ROS

1 (2.4)

–

No CDx

–

29 (100.0)

Small molecule

31 (73.8)

12 (41.4)

Biologic

11 (26.2)

17 (58.6)

Orphan drug

28 (66.7)

20 (69.0)

First in class

15 (35.7)

15 (51.7)

Expedited program

40 (95.2)

24 (82.8)

Approval dates

 1997–2002

1 (2.4)

2 (6.9)

 2003–2008

4 (9.5)

2 (6.9)

 2009–2014

7 (16.7)

9 (31.0)

 2015–2020

30 (71.4)

16 (55.2)